Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Globus Medical, Inc.
GMED
NYSE·Healthcare·Medical - Devices·Mkt cap $10.2B
$80.12
▲ +5.48%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$51.79 - $101.40
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 25.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive product portfolio spanning multiple musculoskeletal specialties
- Strong research and development capabilities driving innovation in implant technology
- Established distribution networks and international market presence
- Regenerative biologic products offering differentiation in treatment options
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Aging global population increasing demand for spine and joint replacement surgeries
Value
Attractively priced below Medical Devices peer average
Momentum
Weak
-13.6% over 3m
Quality
Excellent
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying GMED right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Jul 30, 2026
MAY 7, 2026
Reported EPS of $1.12 vs $0.92 consensus (+21.7% surprise). Revenue of $759.9M vs $740.3M expected (+2.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+21.7%
Next: Jul 30, 2026
Revenue trend · last 8Q
—
—
—
-1%
+18%
+23%
+26%
+27%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$629.7M
$625.7M
$657.3M
$598.1M
$745.3M
$769.0M
$826.4M
$759.9M
Margins · last 8Q
Gross
—
Operating
—
Profit
16.4%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$110.00
▲ +37.3% vs $80.12
Latest: Needham · $117.00 · May 8, 2026
2 analysts covering